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ABSTRACT. Recent developments in biotechnology have resulted in an increased interest in the monitoring
of public attitudes and perceptions of this area of science. The audiences of interest have broadened to include
not only the general public, but also various public opinion leadership groups and groups involved in
decision-making.
In general, leadership groups are more informed about biotechnology than the general public, and are more
likely to see the benefits of biotechnology outweighing the risks. A special subgroup of the population that
has not been polled previously is the business community. This is an important group whose opinions should
be counted.
In July, 1985, Monsanto Company conducted a survey of 400 business executives, equally divided between
Ohio and South Carolina, concerning their attitudes about the growing industry of biotechnology. South
Carolina was chosen as a state representative of the South; Ohio was chosen as a state representative of the
Midwest. Results indicated that the majority of business executives are not familiar with biotechnology.
However, many in this group see biotechnology as a good financial investment. Results of the survey also
reinforced the conclusion that most members of society are not very well informed about biotechnology. This
produces a high "biotech illiteracy" rate among consumers that can greatly hamper the acceptance of bio-
technology products by the public.
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INTRODUCTION
Over the past several years, interest has increased in
monitoring public attitudes toward and perceptions of
biotechnology. The audiences of interest have broadened
to include not only the general public, but also various
public opinion leadership groups and groups involved in
decision-making.
Surveys of the general public (Powledge 1983) have
concentrated on measuring the general awareness of
biotechnology and such specific aspects as genetic engi-
neering and gene splicing. A second focus has been the
public's perception of whether the benefits of biotech-
nology outweigh the risks. The survey results indicate
that, in general, the public is uninformed about biotech-
nology and its benefits to society.
Surveys of various leadership groups (Miller 1985)
have not only concentrated on measuring awareness of
biotechnology, but also measuring perceptions of its im-
pact in various areas (e.g., medicine, agriculture). In
general, leadership groups are more informed about bio-
technology than the general public and are more likely to
see the benefits of biotechnology outweighing the risks.
'Manuscript received 13 November 1986 and in revised form 6
April 1987 (#86-51).
A special subgroup of the population that has not been
polled has been the business community. How informed
are business executives about biotechnology and its bene-
fits? It stands to reason that this subgroup could play an
important role in promoting the benefits of biotech-
nology. This is an important group whose opinions
should be counted.
ATTITUDES OF THE GENERAL PUBLIC TOWARD
BIOTECHNOLOGY. According to a Yankelovich, Skelly,
and White survey in 1983 (Powledge 1983), 70% of the
American public had heard of the term "genetic engi-
neering." However, as the researchers point out, this does
not indicate that people understand or know what bio-
technology is. They also found that almost two-thirds of
the sample felt that cautious steps should be taken in the
development of genetic engineering. Even though almost
40% of the respondents felt that the benefits of bio-
technology would outweigh any problems, another 30%
could not voice an opinion on the subject. This is an
indication of the number of people who do not know
enough about biotechnology to make an intelligent deci-
sion concerning its risk/benefit ratio.
An area where the public does seem to support the use
of biotechnology is in the diagnosis and cure of disease.
A Business W^ei/Harris Poll (1985) indicated that the
170 G. F. BARTON Vol. 87
majority of Americans favor genetic testing and would
even submit to it if it was used to diagnose or cure a fatal
or genetic disease. The main fear seems to be that the
government, insurance companies, or employers could
use the information to discriminate against them in some
way. They do not want the test results to be available
to others.
A recent study by Cambridge Reports, Inc. (198*5)
indicated that 44% of the sample had never heard of the
phrase "genetic engineering," or could not verbalize
what they think of when they hear the phrase. Over
one-half (54%) also had not heard of private companies
getting into the field of biotechnology, with an addi-
tional 10% indicating that they were unsure if they had
or not. It appears as if in the last few years the awareness
level of biotechnology has not changed dramatically. Peo-
ple are still unaware of what it is.
ATTITUDES OF VARIOUS LEADERSHIP GROUPS TO-
WARD BIOTECHNOLOGY. In the last three years, more
emphasis has been placed on measuring the attitudes of
various subgroups of the population toward biotech-
nology; specifically, those aware of and interested in the
scientific community and various leadership groups.
Miller (1984) studied the attitudes of academic scientists
and middle- and upper-level government employees
toward biotechnology. All of these individuals were in-
volved in some way with biotechnology policy. The sci-
entists had more positive attitudes toward biotechnology
and tended to be excited about its future. This group was
not in favor of any federal regulations that might jeopar-
dize scientific progress. In contrast, the federal civil
servants were more cautious about biotechnology and
advocated federal control over scientific advances.
These findings are consistent with those of the Na-
tional Science Board (Powledge 1983). From 1979 to
1981, it surveyed individuals who were "knowledgeable"
about, or "interested" in, science. The Board found that
those with some knowledge about science tended to feel
that the benefits of biotechnology would outweigh the
risks. Those who were only "interested" in but not
"knowledgeable" about science tended to be more pessi-
mistic about the benefits. The study concluded that those
with less education tend to be most concerned about the
risk of genetic engineering.
Miller (1985) conducted a study of the attitudes of
religious, environmental, and science policy leaders to-
ward biotechnology. These leadership groups do not con-
sider themselves very well informed about biotechnology
(i.e., only 24% of science policy leaders, 21% of religious
leaders, and 6% of environmental leaders were well in-
formed). However, a majority of all groups felt that the
benefits of biotechnology outweigh the risks.
As one moves from the general public to specific sub-
groups of the population, the level of awareness of bio-
technology increases, as well as support for the belief that
the benefits outweigh the risks. The question remaining
is: Will this same pattern hold true for members of the
business community?
METHODS
In July, 1985, the Monsanto Company retained the Opinion Re-
search Division of Fleishmann-Hillard, Inc. to conduct a survey of
200 business executives in Ohio and another 200 in South Carolina
concerning their attitudes about the growing industry of bio-
technology. South Carolina was chosen as a state that was representa-
tive of the South; Ohio was chosen as a state that was representative
of the Midwest. Co-sponsors of the survey were the Ohio Chamber of
Commerce and the Chamber of Commerce of South Carolina. The
study was exploratory in nature and designed to assess how cognizant
the business sector was of the potential benefits of the biotechnology
industry to the two states.
The list of business executives interviewed was purchased from Dun
and Bradstreet's Marketing Services Division. Dun and Bradstreet
computed the sampling intervals for the study and randomly selected
Ohio companies with annual sales of at least $70 million and South
Carolina companies with annual sales of at least $6 million for inclu-
sion in the study. The list included the names of the chief executive
officers of the companies. All of these individuals received an advance
letter from their state's Chamber of Commerce explaining the study
and asking the executives for their cooperation. The executives were
then called by professional interviewers during business hours and
interviewed. The average length of the interviews was 10 minutes.
Initially, the sample was to be drawn based on annual sales of over
$70 million. This sales level did not present a problem in Ohio
because it has a large industrial base. However, in South Carolina,
which is more rural and less industrialized, the sales level had to be
lowered to $6 million or more in order to have a large enough universe
from which to draw a representative sample. The difference reported
between the two states may be due to the size of companies par-
ticipating and/or industry type. This should be kept in mind when
reviewing the results.
Initially, all executives were read the following introductory para-
graph concerning biotechnology:
"We'll be talking about biotechnology, a method of taking a
specific gene from one type of plant or bacteria and transferring it
to another. The result can include: heartier plants, more resistance
to drought and disease, the creation of bacteria to neutralize haz-
ardous waste, and new ways to produce medicine such as human
insulin."
The executives were then asked questions designed to measure their
level of awareness of the growing industry, their assessment of the
caliber of their state's resources necessary to attract the industry to the
state, and what they felt the future role of the United States would be
in biotechnology.
For purposes of this study, sampling error was defined as the
estimated variance between the observed results, and those that would
be obtained in replicated samples of the same population using the
same research methods. Given this definition and the total sample size
of 400 respondents, the sampling error is ±5 percentage points. This
means that in 19 out of 20 surveys of the same population, using the
same methods, we can expect that the true proportions are within
5 percentage points of the resulting estimates.
Response differences between Ohio and South Carolina executives
were reported as statistically significant when there was only a 5%
chance that an observed difference was not a true difference. The
computation of significant differences between subgroups was based
on the square root of the sum of the estimated variance for each
subgroup.
RESULTS
AWARENESS OF BIOTECHNOLOGY. Fifty-three per-
cent of Ohio business executives were at least somewhat
familiar with biotechnology, whereas only 4 1 % of South
Carolina business executives were at least somewhat
familiar with it (Table 1). South Carolina executives were
more likely than Ohio executives to say that they were
unfamiliar with biotechnology. Sixty percent of South
Carolina executives indicated that they were unfamiliar
with biotechnology; 48% of Ohio executives indicated
that they were unfamiliar with it.
When asked about the involvement of their companies
in the biotechnology industry, only 3 to 5% of all execu-
tives reported that their companies were involved in the
research and development or commercialization of bio-
technological products (Table 2). Most of the companies
that are involved are engaged in research and devel-
opment activities or the manufacturing of equipment for
products related to biotechnology.
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TABLE 1
Percentage of answers (N=400) to the question:
Do you consider yourself to be very familiar, somewhat
familiar, or unfamiliar with this new technology?
TABLE 4
Percentage of answers (N — 400) to the question: Are you aware of
any companies in your state that are now involved in genetic engineering?
Responses
Ohio
(N = 200)
South
Carolina
(N = 200) Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
Very familiar
Somewhat familiar
Unfamiliar
Don't know
12
41
5
36
60"
0
Yes
No
Don't know
17
81"
2
92'
1
^Significantly different from each other at P = 0.05.
TABLE 2
Percentage of answers (N = 400) to the question:
Is your company involved in the research and development
or commercialization of genetic engineering products?
*Significantly different from each other at P = 0.05.
TABLE 5
Percentage of answers (N = 400) to the question:
How interested are you in buying stock in companies
which use this technology for your own portfolio?
Responses
Yes
No
Don't know
Ohio
(N = 200)
5
95
1
South
Carolina
(N = 200)
3
97
1
Responses
Very interested
Somewhat interested
Not very interested
Don't know
Ohio
(N = 200)
16
36
43
6
South
Carolina
(N = 200)
7
34
46
15
The business executives were also asked whether or not
their company intended to move into the biotechnology
industry within the next five years (Table 3). About 90%
of the executives in both states said that their companies
were not planning to do so, with less than 5% in either
state indicating that their companies have plans to move
into this industry.
Not only were the majority of the executives in compa-
nies not involved in biotechnology, but on the whole,
they were also unaware of companies in their respective
states who were involved in biotechnology (Table 4).
South Carolina business executives (92%) were signifi-
cantly more unaware of companies involved in genetic
engineering in their state than Ohio business executives
(81%).
Although executives were not very familiar with bio-
technology, they were somewhat interested in purchasing
stock in companies using this technology (Table 5). Ex-
ecutives in Ohio were more interested in purchasing
stock in corporations using biotechnology than South
Carolina executives. South Carolina executives tended to
be uncertain whether they should purchase stock in these
TABLE 3
Percentage of answers (N — 400) to the question:
What about within the next five years? Is your company
planning to move into this industry in this state?
Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
Yes
No
Don't know
Currently involved
in research
4
88
4
5
1
94
2
3
companies. However, more than 43% of executives in
both states were not very interested in buying stock in
these companies. As can be expected, executives who
were the most knowledgeable about biotechnology were
also the most likely to be interested in buying stock in
these companies.
In general, executives in both states tended to be only
somewhat familiar with biotechnology. The vast majority
were not working in companies involved in bio-
technology or that planned to be in the next five years.
Executives tended to be unaware of companies in their
respective states that are involved in biotechnology. Even
though they were unaware of these factors, many were at
least somewhat inclined to purchase stock in companies
involved in biotechnology.
Executives in South Carolina were significantly more
unfamiliar with biotechnology (Table 1), significantly
more unaware of companies in their state involved in
biotechnology (Table 4), and less likely to want to buy
stock in biotechnology companies than executives in
Ohio (Table 5).
T H E POTENTIAL FOR BIOTECHNOLOGY IN OHIO AND
SOUTH CAROLINA. Ohio executives were most likely
to believe that biotechnology has enormous potential for
their business sector than were South Carolina executives
(Table 6). More than 25% of executives from both states
did not know how much biotechnology would affect the
business communities in their respective states. Overall,
executives in both states felt that biotechnology offers at
least some potential for their state's business sector.
South Carolina executives (32%) were significantly
more likely to feel that their state is very competitive in
attracting high technology industries than Ohio execu-
tives (22%). Conversely, Ohio executives (39%) were
significantly more likely to feel Ohio is not very com-
petitive in attracting high technology industries than
were South Carolina executives (25%) (Table 7).
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TABLE 6
Percentage of answers (N — 400) to the question: How much
potential do you think biotechnology (genetic engineering) has
for the business sector in Ohio/'South Carolina?
Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
Very great potential
Some potential
Little potential
Don't know
32
36
5
28
23
43
8
27
TABLE 7
Percentage of answers (N = 400) to the question: Compared to other
states, do you consider OhiolSouth Carolina very, somewhat, or not very com-
petitive in attracting high technology industries of which genetic engineering
Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
Very competitive
Somewhat competitive
Not very competitive
Don't know
22*
34
39**
7
32
37
*Significantly different from each other at P = 0.05.
**Significantly different from each other at P — 0.05.
Consistent with this last result, the vast majority
(80%) of Ohio executives felt that Ohio should increase
its efforts to encourage the development of biotechnology
industries (Table 8). South Carolina executives were sig-
nificantly more likely to indicate that they don't know if
their state should increase its efforts to attract the bio-
technology industry.
Respondents were asked how much their states would
benefit from biotechnology in the areas of agriculture,
business investments, pharmaceuticals for the state's
health industry, and employment (Table 9). A majority
of executives in both states believed that genetic engi-
neering could benefit all these areas somewhat or a great
deal. Biotechnology was seen as being most beneficial to
the agricultural segment and business investments.
There were no significant differences between Ohio and
South Carolina executives on these questions.
Executives were also asked how much five different
business sectors might benefit from the development of
TABLE 8
Percentage of answers (N = 400) to the question: Do you believe Ohio/
South Carolina state government should make a greater effort to encourage the
development of the genetic engineering industry?
Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
Yes, make more
effort
No, should not
Don't know
80*
12
69*
9
23**
*Significantly different from each other at P = 0.05.
**Significantly different from each other at P — 0.05
TABLE 9
Percentage of answers (N — 400) to the question: This new technology
could potentially benefit Ohio/South Carolina in a number of ways. Do you
see genetic engineering benefiting the state a great deal, somewhat, or very little
in each of the following areas?
Development of heartier
plants and more productive
animals for the state's
agricultural industry?
Ohio (N = 200)
South Carolina (N = 200)
New business investment in
the state?
Ohio (N = 200)
South Carolina (N = 200)
New pharmaceuticals for the
state's health industry?
Ohio (N = 200)
South Carolina (N = 200)
New jobs created as a result
of the new technology?
Ohio (N = 200)
South Carolina (N = 200)
Great
deal
53
51
40
36
39
31
33
35
Responses
Somewhat
35
33
44
46
38
44
51
46
<%>
Very
little
5
4
10
8
13
9
10
10
Don't
know
8
13
7
10
10
17
7
10
biotechnology (Table 10). A majority of executives in
both states thought that it will be very beneficial to
agriculture. In Ohio, a similar majority felt that bio-
technology will be very beneficial to Ohio's medicine and
pharmaceutical sectors. Ohio executives were signifi-
cantly more positive about the benefits to this sector than
South Carolina executives.
Respondents did not see the banking/investment sec-
tor, computer/information system sector, or the construc-
tion sector benefitting a great deal from the introduction
of biotechnology (Table 10). Ohio executives were sig-
TABLE 10
Percentage of answers (N = 400) to the question: How much
might each of the following OhiolSouth Carolina business sectors benefit
from the development of this new technology?
Sectors
Agricultural:
Ohio (N = 200)
South Carolina (N = 200)
Medicine/pharmaceutical:
Ohio (N = 200)
South Carolina (N = 200)
Banking/investment:
Ohio (N = 200)
South Carolina (N = 200)
Computer/information systems:
Ohio (N = 200)
South Carolina (N = 200)
Construction:
Ohio (N - 200)
South Carolina (N = 200)
Great
deal
58
58
59*
46*
16
22
14
18
11
12
Responses
Somewhat
32
27
26*
36*
46
40
36
33
43
37
(%)
Very
little
1
2
5
3
25*
15*
33*
22*
32
26
Don't
know
10
14
11
16
14*
24*
18*
29*
15*
25*
* Responses (Ohio vs. South Carolina) significantly different at
P = 0.05.
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nificantly more likely to feel that biotechnology will have
very little effect on the banking and investment sector,
and the computer and information sector. South Carolina
executives were more likely to indicate that they did not
know what effect biotechnology will have on these three
sectors.
Executives were also asked to rate their respective state
in terms of how strong it was in different resource areas
(Table 11). Ohio and South Carolina executives differed
significantly. Ohio executives felt they have very strong
or strong resources in the area of science education. South
Carolina executives viewed their science education as
being not very strong, or they don't know how strong it
is. On the other hand, South Carolina executives felt that
their state was stronger in the area of offering tax breaks
to companies involved in biotechnology.
Executives rated their states comparably in the areas of
university research capabilities, industry research and de-
velopment, and business expansion (Table 11). An im-
portant finding was that executives from both states view
their state's weak points as being a lack of public and
business awareness of biotechnology and its benefits.
Overall, executives were divided as to the potential bio-
TABLE 11
Percentage of answers (N = 400) to the question: To promote the
development of genetic engineering, states need various resources. Do you rate
Ohio/'South Carolina very strong, strong, or not very strong in each area?
Responses (%)
Resources
Very Not very Don't
strong Strong strong know
Its university research
capabilities:
Ohio (N = 200) 42 52 5 2
South Carolina (N = 200) 35 46 13 7
Current amount of industrial
research and development in
areas like agriculture and
medicine:
Ohio (N = 200)
South Carolina (N = 200)
Sources of capital for
business expansion:
Ohio (N = 200)
South Carolina (N = 200)
Quality of science education
in secondary public education:
Ohio (N = 200)
South Carolina (N = 200)
Tax breaks/other incentives
to attract genetic
engineering businesses to
the area:
Ohio (N = 200) 10* 24 52* 15
South Carolina (N = 200) 22* 33 23* 23
Awareness among business and
government leaders of genetic
engineering and its benefits:
Ohio (N = 200) 3 25 65 8
South Carolina (N = 200) 3 17 68 12
Public awareness of genetic
engineering and its benefits:
Ohio (N = 200) 0 7 87 6
South Carolina (N = 200) 1 4 90 6
* Responses (Ohio vs. South Carolina) significantly different at
P = 0.05.
technology offers their state's business sectors (Table 6).
The majority agree that biotechnology will benefit agri-
culture, business investments, pharmaceuticals, and em-
ployment, with the most benefit accruing to agriculture
and business (Table 9).
Ohio executives were most likely to feel that bio-
technology offers potential for the business sector (Table
10), and that Ohio should increase efforts to attract bio-
technology industries. They felt that biotechnology will
make more positive contributions to the pharmaceutical
industry and have little affect on banking and investment
(Table 10). They also viewed their state's educational
resources as being a very strong attraction for bio-
technology industries. On the other hand, South Caro-
lina executives felt that their state was very strong in
offering strong tax breaks to attract industry.
U.S. INVOLVEMENT IN BIOTECHNOLOGY. Finally,
the executives were asked if they expected the United
States to retain its lead in the field of biotechnology in the
next decade (Table 12). More than 73% of the executives
said that the United States will retain this lead. Twelve
percent felt that another country will take the lead;
slightly more than this said that they don't know who
will be the leader.
DISCUSSION
The majority of business executives surveyed in this
study were not very familiar with biotechnology, and
were not working for companies involved in or planning
to become involved with biotechnology during the next
five years. Business executives are more likely to be famil-
iar with biotechnology than the general public, but they
are not as well informed as science policy leaders or
religious leaders. However, many executives see bio-
technology as a good financial investment and are willing
to purchase stock in these companies.
The results of this survey reinforce the conclusions
reached by those involving the general public and specific
leadership groups, namely that most members of society
are not very well informed about biotechnology. This
results in a high "biotech illiteracy" rate among con-
sumers that can greatly hamper the acceptance of bio-
technology products by the public. Recognition of the
need for a public education program to enlighten con-
sumers about the benefits of biotechnology have been
voiced by members of the scientific community (Edwards
1983a, 1983b, Price 1985).
TABLE 12
Percentage of answers (N — 400) to the question: The United States is
now the world leader in genetic engineering, followed by Japan and some
European countries. Do you expect the United States will continue to retain
this lead during the next decade, or do you think another country will take
the lead?
Responses
Ohio
(N = 200)
South
Carolina
(N = 200)
U.S. will retain the
lead
Another country will
take the lead
Don't know
74
12
15
73
12
16
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